Actively Recruiting
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Led by Shanxi Bethune Hospital · Updated on 2024-10-22
50
Participants Needed
1
Research Sites
100 weeks
Total Duration
On this page
Sponsors
S
Shanxi Bethune Hospital
Lead Sponsor
A
Antengene Corporation
Collaborating Sponsor
AI-Summary
What this Trial Is About
This clinical trial studies the efficacy and safety of selinexor combined with HAD or CAG regimen in the treatment of relapsed or refractory acute myeloid leukemia
CONDITIONS
Official Title
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 60 years old
- Diagnosis of relapsed or refractory acute myeloid leukemia, excluding AML-M3
- Meet criteria for refractory AML including failure to achieve remission after 2 induction chemotherapies, relapse within 6 months of first remission, multiple relapses, or persistent extramedullary leukemia
- Meet criteria for recurrent AML including presence of naive cells in blood or bone marrow or extramedullary recurrence
- Bone marrow shows active or reduced cell growth
- Eastern Oncology Collaborative Group Physical Status Assessment score of 0 to 2
You will not qualify if you...
- Presence of cerebral hemorrhage
- Pregnancy
- Mental illness or other condition preventing study participation
- Severe arrhythmia or abnormal ECG with QT interval over 500 ms
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tao Wang
Taiyuan, Shanxi, China, 030000
Actively Recruiting
Research Team
T
Tao Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here